Eli Lilly and Company (LLY)
Sous-évaluéFondamental
69
Prix
$1157.08
Capitalisation boursière
$1.05T
Partie 1 · Ce que vaut l'entreprise
Vue d'ensemble
Eli Lilly discovers, develops and sells prescription medicines, concentrating on diabetes and obesity, oncology, immunology and neuroscience. Its current growth is dominated by tirzepatide, the molecule sold as Mounjaro for diabetes and Zepbound for weight loss, which together now account for more than half of company revenue. Drugs reach patients through wholesalers, pharmacies and, increasingly, direct-to-consumer channels for the weight-loss franchise.
Comment l'entreprise gagne de l'argent
Revenue comes almost entirely from selling patented medicines at prices that reflect years of research and clinical-trial spending rather than manufacturing cost. A drug protected by patent can be priced with little direct competition; once patents expire, generic or biosimilar versions typically cut that product's sales sharply within a few years, which is why the pipeline behind today's bestsellers matters as much as the bestsellers themselves.
Chiffre d'affaires par segment
Tirzepatide sold for type 2 diabetes, the single largest product and the fastest-growing major one in 2025.
The rest of the portfolio across diabetes, oncology, immunology and neuroscience, none individually broken out in the annual results.
The same molecule, tirzepatide, sold for chronic weight management — a newer indication already generating more than a fifth of total revenue.
A breast-cancer treatment and the largest product outside the tirzepatide franchise.
Avantage concurrentiel
Brevets et licences · LargePatents on approved molecules give Lilly years of protection from direct competition, and the regulatory approval process itself is a barrier few companies can clear. The tirzepatide franchise adds a manufacturing edge too: building the capacity to produce injectable GLP-1 drugs at this scale takes years, which is currently limiting how fast even a well-funded rival like Novo Nordisk can respond.
Ce qui stimule la demande
DéfensifMost of the portfolio treats chronic conditions — diabetes, cancer, autoimmune disease — that patients keep treating regardless of the economic cycle. The newer weight-loss business is more exposed to household budgets since much of it is paid out of pocket or with limited insurance coverage, but it still sits on top of an otherwise defensive base.
Principaux risques
- Patent expiration and biosimilar competition — The company identifies the loss of intellectual-property protection on key products, and the entry of generic or biosimilar competitors once patents expire, as a risk to future revenue.
- Government and payer pricing pressure — Continued pricing pressure from governmental and private payers, including Medicare drug-price negotiation under U.S. law, affects pricing, reimbursement and patient access to Lilly's medicines.
- Concentration in a few products — The company depends on a relatively small number of products and a consolidated supply chain for a significant share of total revenue, so a manufacturing, safety or competitive setback for any one of them has an outsized effect.
Les arguments en faveur
Buyers argue that the tirzepatide franchise still has years of volume growth ahead as obesity treatment expands globally, that manufacturing scale-up gives Lilly a lead over Novo Nordisk that is hard to close quickly, and that a broad pipeline beyond GLP-1 drugs reduces the company's dependence on any single therapeutic area.
Les arguments contre
Sellers fear that more than half of revenue now rests on one molecule facing well-capitalized competition and looming price cuts from Novo Nordisk, that government price negotiation will keep compressing margins on older products, and that a business this concentrated in a handful of drugs is unusually exposed to a single clinical, manufacturing or pricing setback.
Written by the editors, published on 18 août 2026
Direct competitors
Who this company fights with for the same customers
No editorial profile for this company yet
No competitor list for this company yet.
Bilan & Liquidités
Chiffre d'affaires
$79.67B
12 derniers mois (au 30/06/2026)
Résultat net
$26.71B
12 derniers mois (au 30/06/2026)
Flux de trésorerie libre
-
Capitaux propres totaux
$26.54B
Passif total
$85.94B
Ratio de liquidité général
1.35
Couverture des intérêts
-
Dette/EBITDA
1.32
Bénéfice par action
Chiffre d'affaires & Résultat net
Flux de trésorerie libre
Décomposition du résultat
État historique
Marges dans le temps
La dette dans le temps
Le poids de la dette
Grille de la croissance
Croissance — Chiffre d'affaires
Estimation de la juste valeur
Juste valeur
$1551.10
Prix actuel
$1157.08
Marge de sécurité
+25.4%
Fourchette de juste valeur
$1030.42 - $2071.78
Écart entre les méthodes de valorisation utilisées, pas un intervalle de confiance calibré statistiquement.
Méthodes d'estimation
Indicateurs de valorisation
Ratio P/E
38.83
ROE
77.8%
Ratio P/B
32.15
P/FCF
-
Marge brute
83.4%
ROIC
-
Radar de rentabilité
Création de valeur (avantage concurrentiel)
ROIC
-
WACC
7.7%
ROIC − WACC
-
Critères d'analyse fondamentale
Réussi (16)
- EPS shows upward trend
- Price CAGR 31.66%
- Gross Margin 83.4%
- Debt/Equity ratio
- Current Ratio
- Debt/EBITDA
- Return on Tangible Assets
- ROE 92.6%
- Revenue Growth 5Y 21.6%
- Analyst Consensus 79% Buy
- Earnings Surprise avg 24.8%
- PEG Ratio 1.51
- Earnings Quality (OCF/NI) 1.05
- Share Dilution -0.6%
- Net Margin Trend 33.5% vs 25.9%
- Piotroski F-Score 8/9
Échoué (4)
- P/B Ratio 32.15
- Low reliance on intangibles
- Price below Graham Number
- DCF valuation (Unknown)
Indisponible (7)
- ROIC NaN%
- P/FCF NaN
- Dividend Payout NaN%
- Operating Margin NaN%
- Positive Free Cash Flow
- CapEx intensity
- Interest Coverage
Score F de Piotroski
Santé financière solide
Qualité des bénéfices
Qualité élevée : bénéfices soutenus par la trésorerie
Dilution du capital
Rachat d'actions. Favorable aux actionnaires
Participations institutionnelles
Gouvernance
Équipe dirigeante
| Nom | Titre | Âge |
|---|---|---|
| Mr. David A. Ricks | Chairman, President & CEO | 57 |
| Mr. Lucas E. Montarce | Executive VP & CFO | 48 |
| Dr. Daniel M. Skovronsky M.D., Ph.D. | Chief Scientific & Product Officer and President of Lilly Research Laboratories | 52 |
| Ms. Anat Hakim J.D. | Executive VP, General Counsel & Secretary | 56 |
| Mr. Jacob S. Van Naarden | Executive VP, President of Lilly Oncology & Head of Corporate Business Development | 40 |
| Mr. Donald A. Zakrowski | Senior VP of Finance & Chief Accounting Officer | - |
| Mr. Diogo Rau | Executive VP and Chief Information & Digital Officer | 50 |
| Mr. Michael Czapar | Senior Vice President of Investor Relations | - |
| Mr. Eric Dozier | Executive VP & Chief People Officer | 58 |
| Mr. Ilya Yuffa | Executive VP and President of Lilly USA & Global Customer Capabilities | 50 |
Risque d'audit
8
Risque du conseil
5
Risque de rémunération
5
Risque droits des actionnaires
9
Partie 2 · Le prix et le moment d'entrer
Cette partie ne dit pas si l'entreprise vaut la peine : elle aide à choisir quand l'acheter, une fois que les fondamentaux vous ont convaincu. À l'intérieur : analyse technique, potentiel, baisses historiques, exposition gamma.
Documents
- Voir le document
Rapport annuel (10-K)
Un aperçu annuel de l'activité, des résultats financiers et des risques de l'entreprise.
Déposé le 2026-02-12
- Voir le document
Rapport trimestriel (10-Q)
Une mise à jour de la performance financière des trois derniers mois.
Déposé le 2026-08-05
- Voir le document
Rapport d'événement important (8-K)
Un avis concernant un événement important, comme un changement de direction ou une annonce majeure.
Déposé le 2026-08-05
via SEC EDGAR
Historique des résultats
via SEC EDGAR
Latest News
Recent headlines for LLY, sourced from Markets Gazette.
- 16h agoNEUTRALAdding Lilly’s new drug to Zepbound helped people lose more weight — but there were more side effects
Eli Lilly's experimental amylin drug, when added to Zepbound, demonstrated increased weight loss in trials. However, this combination also led to a higher incidence of side effects. The company is exploring this drug's potential for both weight management and diabetes treatment. While the enhanced weight loss is a positive development, the increased side effect profile introduces a note of caution for investors. The net effect on the stock will likely depend on the severity and manageability of these side effects versus the efficacy gains.
- 13d agoPOSITIVELilly’s Newest Bull Says Near 300% Rally Is Only the Beginning
Eli Lilly and Company has experienced a remarkable surge of approximately 300% in its stock value over the past four years, following the approval of its first GLP-1 drug. This impressive performance has propelled the company's market capitalization beyond $1 trillion, establishing it as the preeminent pharmaceutical firm globally. The sustained growth trajectory, driven by its innovative GLP-1 treatments, suggests continued strong investor confidence and potential for further expansion in the lucrative obesity and diabetes markets. Analysts remain bullish, anticipating that this rally is far from over, indicating a robust outlook for the company.
- 29d agoPOSITIVELilly to Buy Merida for $2.88B in Autoimmune Push
Eli Lilly and Company has announced plans to acquire Merida Biosciences Inc. for up to $2.88 billion in cash. This strategic move aims to bolster Lilly's presence in the autoimmune and allergic diseases sector, diversifying its portfolio beyond its current dominance in weight-loss and diabetes treatments. The acquisition underscores Lilly's commitment to expanding its therapeutic reach and leveraging its financial strength to secure growth opportunities in promising medical fields. Investors may view this as a positive step towards sustained long-term growth and market leadership.
- 8/31/2026POSITIVELilly to Buy Merida for $2.88 Billion in Autoimmune Push
Eli Lilly and Company is set to acquire Merida Biosciences Inc. for up to $2.88 billion in cash, signaling a strategic expansion into autoimmune and allergic diseases. This move diversifies Lilly's portfolio beyond its highly successful weight-loss and diabetes drugs, Zepbound and Mounjaro. The acquisition is part of Lilly's aggressive deal-making strategy, with over $20 billion invested in 2026 alone, aimed at bolstering its pipeline with early-stage medicines to secure future blockbuster treatments. Investors may view this as a positive step towards sustained long-term growth and innovation.
- 8/12/2026NEGATIVEEli Lilly is suing pharmacies and peptide vendors over early sales of the next big weight-loss drug: retatrutide
Eli Lilly and Company has initiated legal action against pharmacies and peptide vendors accused of prematurely selling compounded versions of its upcoming weight-loss drug, retatrutide. This move aims to protect the integrity of its intellectual property and ensure the drug's eventual regulated release. The lawsuit highlights the intense market anticipation for retatrutide, a drug poised to be a significant player in the lucrative obesity treatment market. For investors, while the legal action may create short-term noise, it underscores Lilly's commitment to safeguarding its pipeline and maximizing the commercial potential of its innovative therapies.
- 8/11/2026POSITIVEEli Lilly Surges, Novo Nordisk Slips in Weight-Loss War
Eli Lilly and Company (NYSE:LLY) has reported a significant 48% surge in second-quarter revenue, reaching US$23 billion, driven by its blockbuster GLP-1 weight-loss and diabetes treatments. Sales of Mounjaro and Zepbound combined accounted for nearly 65% of total revenue, with Mounjaro alone seeing a 91% jump. The company has consequently raised its full-year revenue forecast to US$85-87 billion. This strong performance, coupled with a 7% stock increase in early trading, highlights Lilly's robust market position and growth potential in the highly competitive weight-loss drug sector, outperforming rivals like Novo Nordisk.
- 8/5/2026POSITIVELilly’s revenue soars 48%, driven by demand for its GLP-1s
Eli Lilly and Company reported a remarkable 48% surge in revenue, significantly exceeding expectations. This growth was primarily fueled by robust demand for its GLP-1 drugs, Mounjaro and Zepbound, which are indicated for Type 2 diabetes and weight loss respectively. The strong performance underscores the increasing market penetration and therapeutic success of Lilly's innovative treatments in high-demand areas. Investors will likely view this as a strong indicator of sustained future earnings growth and market leadership for the pharmaceutical giant.
via Markets Gazette